| Name | Unterstützung | Language | Verfügbarkeit | Datum der Ausstellung | Preis | ||
|---|---|---|---|---|---|---|---|
|
PDF |
Englisch |
gültig |
16.01.2018 |
193,00 € |
|
||
Details
This guideline discusses the necessary and recommended data for selecting appropriate breakpoints and quality control ranges for antimicrobial agents.
Clinical and Laboratory Standards Institute guideline M23—Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters offers guidance for developing breakpoints and QC ranges for antimicrobial susceptibility tests against aerobic and anaerobic bacteria, as well as selected fungi, according to CLSI antimicrobial susceptibility testing standards. It describes the data used by the Subcommittees on Antimicrobial Susceptibility Testing and Antifungal Susceptibility Tests to establish these breakpoints and QC ranges for antimicrobial agents, including microbiological data, pharmacokinetic and pharmacodynamic characteristics, and clinical data. As antimicrobial agents are used in practice, additional experience accrued may be used to reassess breakpoints or QC ranges. Users of these guidelines should understand that susceptibility test results cannot predict clinical outcomes with absolute certainty. They should be used along with best clinical judgment and laboratory support to most effectively serve the patient.
Zusätzliche Information
| Autor | Clinical and Laboratory Standards Institute (CLSI) |
|---|---|
| Veröffentlicht von | CLSI |
| Document type | Normen |
| Thema | /subgroups/17907 |
| Ausgabe | 5 |
| EAN ISBN | 9781562388428 |
| Seitenzahl | 84 |
| Ersetzt | CLSI M23-Ed4,CLSI M23-A3,CLSI M23A2 |
| Schlagwort | CLSI M23-Ed5 |
